helping reduce the symptoms of cystic fibrosis. However, these medications are only effective in people with specific CFTR mutations. Therefore, doctors will choose the type of CTFR modulator ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Cystic fibrosis (CF) is a life-threatening genetic ... a condition affecting up to 50% of adults with CF. CF is caused by ...

Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

ReCode Therapeutics is set to secure up to $15m in additional funding from the Cystic Fibrosis Foundation ... stemming from mutations in the CFTR gene. The company’s lead programmes, RCT2100 ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not ... of people living with cystic fibrosis,” said Reshma ...

An additional 94 non-F508del CFTR mutations and a boxed warning on liver injury and liver failure were included in the updated prescribing information. 1507_1515del9, 2183A→G, A1067P ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...